These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 17892976)
1. Antiplatelet agents make a comeback in ST-elevation myocardial infarction. Wiviott SD; de Lemos JA Am Heart J; 2007 Oct; 154(4):603-6. PubMed ID: 17892976 [No Abstract] [Full Text] [Related]
2. [Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction]. Koziński M; Grześk G; Kubica J Kardiol Pol; 2012; 70(2):206-12. PubMed ID: 22427098 [No Abstract] [Full Text] [Related]
3. Ticagrelor--is there need for a new player in the antiplatelet-therapy field? Schömig A N Engl J Med; 2009 Sep; 361(11):1108-11. PubMed ID: 19717845 [No Abstract] [Full Text] [Related]
4. Role of ticagrelor in clopidogrel nonresponders: resistance is futile? Tapp L; Shantsila E; Lip GY Circulation; 2010 Mar; 121(10):1169-71. PubMed ID: 20194888 [No Abstract] [Full Text] [Related]
5. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891 [TBL] [Abstract][Full Text] [Related]
6. Ticagrelor in ACS: redefining a new standard of care? Stone GW Lancet; 2010 Jan; 375(9711):263-5. PubMed ID: 20079529 [No Abstract] [Full Text] [Related]
7. Intensive antiplatelet therapy for reduction of ischaemic events. Ramaraj R Lancet; 2008 Aug; 372(9638):531; author reply 532. PubMed ID: 18707975 [No Abstract] [Full Text] [Related]
8. The year in interventional cardiology. Dixon SR; Grines CL; O'Neill WW J Am Coll Cardiol; 2010 May; 55(20):2272-86. PubMed ID: 20466207 [No Abstract] [Full Text] [Related]
9. Antiplatelet therapy beyond 2012: role of personalized medicine. Tantry US; Budaj A; Gurbel PA Pol Arch Med Wewn; 2012; 122(6):298-305. PubMed ID: 22751292 [TBL] [Abstract][Full Text] [Related]
10. Ischaemia versus bleeding: the art of clinical decision-making. Stone GW Lancet; 2009 Feb; 373(9665):695-6. PubMed ID: 19249613 [No Abstract] [Full Text] [Related]
11. Approaching an age of reason with antiplatelet therapy. Ajani AE; Lefkovits J Lancet; 2008 Apr; 371(9621):1315-6. PubMed ID: 18424309 [No Abstract] [Full Text] [Related]
15. Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. Orban M; Riegger J; Joner M; Tada T; Okrojek R; Hausleiter J; Kastrati A; Massberg S; Sibbing D Platelets; 2012; 23(5):395-8. PubMed ID: 22671583 [TBL] [Abstract][Full Text] [Related]
16. TRILOGY ACS: prasugrel of benefit only after angiography? Swaminathan RV; Feldman DN Lancet; 2013 Aug; 382(9892):580-2. PubMed ID: 23953376 [No Abstract] [Full Text] [Related]
17. [Myocardial infarction: Role of new antiplatelet agents]. Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430 [TBL] [Abstract][Full Text] [Related]
20. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM; Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]